View Valuation20/20 Biolabs 향후 성장Future 기준 점검 2/620/20 Biolabs 의 수익은 연간 24.4% 감소할 것으로 예상되는 반면, 연간 수익은 66.4% 로 증가할 것으로 예상됩니다. EPS는 연간 1.7% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-24.4%이익 성장률-1.65%EPS 성장률Medical Equipment 이익 성장16.1%매출 성장률66.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트21 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 1720/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).공시 • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.공시 • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.이익 및 매출 성장 예측NasdaqCM:AIDX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20252-4-2-2N/A9/30/20252-3-2-2N/A6/30/20252-4-2-2N/A3/31/20252-5-2-2N/A12/31/20242-6-3-3N/A9/30/20242-6-3-3N/A6/30/20242-5-4-4N/A3/31/20241-6-4-4N/A12/31/20231-6-5-4N/A9/30/20232-6-3-3N/A6/30/20233-5-2-1N/A3/31/20237-212N/A12/31/202211256N/A9/30/202214455N/A6/30/202217644N/A3/31/202214422N/A12/31/2021102-1-1N/A6/30/20190-2N/A-2N/A3/31/20190-2N/A-2N/A12/31/20180-1N/A-1N/A9/30/20180-1N/A-1N/A6/30/20180-1N/A-1N/A3/31/20180-1N/A-1N/A12/31/20170-1N/A-1N/A9/30/20170-1N/A-1N/A6/30/20170-1N/A-1N/A3/31/20170-2N/A-2N/A12/31/20160-2N/A-2N/A12/31/20151-2N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: AIDX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: AIDX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: AIDX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: AIDX 의 수익(연간 66.4%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: AIDX 의 수익(연간 66.4%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: AIDX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 10:43종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스20/20 Biolabs, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael OkunewitchMaxim Group
공시 • May 1720/20 Biolabs, Inc. announced delayed 10-Q filingOn 05/15/2026, 20/20 Biolabs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Apr 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$19k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.9m free cash flow). Negative equity (-US$19k). Earnings have declined by 55% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (US$18.9m market cap).
공시 • Mar 1320/20 Biolabs Highlights Advantages of Its Patented Protein Biomarker Technology for Multi-Cancer Early Detection20/20 BioLabs provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease. Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact. Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection: In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced. In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis. These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms. Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense. Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. Those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs. Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028. The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access. As coverage decisions are made, the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection.
공시 • Feb 2520/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities20/20 BioLabs announced the launch and commercial availability of its OneTest for L longevity solution. The solution uses IBM w Watsonx.ai - an integrated AI application development studio - to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. The test is now available for purchase. The OneTest for L longevity solution uses IBM w Watsonx., an integrated AI application development studio to analyze data, to help individual track chronic inflammation associated with several large chronic diseases. The test is currently available for purchase. The One Test for L longevity solution uses IBM W Watsonx.ai to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. The product provides personalized, evidence-based dietary recommendations to help individuals better understand patterns in their biomarker levels and associated disease risks. The scientific publications being analyzed by the algorithms are curated by Dr. James R. Hebert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™? (DII®?). 20/20 BioLabs' OneTest has neither sought nor received FDA approval and is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs. IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity. The company offers two families of lab tests under the OneTest brand. OneTest™? for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for L longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest's affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. 20/20 BioLabs's pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab.